Analyst Price Targets — CSLLY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 9, 2022 7:01 pm | Chris Cooper | Goldman Sachs | $153.50 | $51.49 | TheFly | CSL reinstated with a Neutral at Goldman Sachs |
Latest News for CSLLY
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.
CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
Australia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
Carlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CSLLY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.